Searched for
TRASTUZUMAB PRICE
AstraZeneca's Enhertu gets regulatory approval in India for first-line HER2-positive breast cancerAstraZeneca Pharma India has secured approval from India's drug regulator for its smart chemotherapy drug Enhertu. This allows for its impo...- Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...
- Govt asks manufacturers to cut price of 3 anti-cancer drugsThe government has directed manufacturers to lower prices of Trastuzumab, Osimertinib, and Durvalumab after exempting them from customs dut...
- Glenmark Pharma slashes price of breast cancer drug TrastuzumabTrastuzumab is used in the treatment of a particular type of breast cancer -- HER2-positive, and the company markets its version in India u...
- Biocon rises 5% after launch of Ogivri in US marketBiotechnology major Biocon and drug firm Mylan NV on Monday announced the launch of biosimilar Ogivri, used for treatment of certain breast...
- Buy Biocon, target Rs 880: Phillip Capital (India)Buy Biocon at a price target of Rs 880.
- Biocon shares surge 15%; brokerages upbeatBiocon rose 15%, closing at Rs 514, and the USFDA development sparked a revision of target price for its shares across brokerages.
- Buy Biocon Ltd. target Rs 560 : ICICI DirectBuy Biocon Ltd. at a price target of Rs 560.
- Breast cancer biosimilar approval delayed as US FDA reviews additional information by Biocon, MylanBiocon and Mylan have together developed the trastuzumab biosimilar, which is a copy of a complex biologic drug developed by Swiss biotech ...
- Roche, Emcure may end pact to make 2 blockbuster drugsEmcure is still the distributor for those two drugs in India. Roche had handed out the manufacturing and marketing of trastuzumab and ritux...
- Delhi High Court gives Biocon, Mylan green light to market blockbuster biosimilar for three cancersThe court’s latest move, which allows the companies to use Roche’s product data in their package inserts, is expected to allow Biocon and M...
- Mylan and Biocon make USFDA submission for proposed biosimilar trastuzumabThe submitted BLA includes a comprehensive package of analytical similarity, nonclinical and clinical data that consists of two pharmacokin...
- Biotech giant Roche takes NPPA to court over cap on injection priceOn May 9, the NPPA issued a notification capping the price of trastuzumab 440mg/50ml injections at Rs 55,812.29 per pack.
- Zydus Cadila launches copy of Roche’s breast cancer drug HerceptinZydus Cadila has introduced a breast cancer drug in India that is a copy of Swiss giant Roche’s product Herceptin, which had global sales o...
- Biocon ups generic war with nod for Roche's cancer drug cloneBiocon officials confirmed the development to ET but didn't shed light on how soon the company would be ready to bring the biosimilar to th...
- DIPP may seek information from DCGI to manufacture generic version of Roche's anti-cancer drugWorried over the exorbitant prices of the drug in the Indian market, the ministry urged the DIPP to invoke this section.
- Compulsory licence: Health Min submits details of ' trastuzumab' to DIPPCL can be invoked by a national government allowing a company to produce a patented product without the consent of the patent owner in publ...
- Swiss-based Roche to produce two cancer drugs locally with Emcure Pharma: GovtRoche has entered into an agreement for a transfer technology project with Emcure for local manufacturing of its two patented cancer drugs.
- DIPP seeks details on 3 cancer drugs for compulsory licencingDIPP has sought details from the Health Ministry regarding three medicines sold by multinationals in India to make them affordable.
- Cancer drugs made by Emcure, Roche still expensive for patientsLast year, Swiss drug maker Roche, said it had signed a deal with Emcure Pharma to manufacture low-cost versions of its breast cancer drug.
Load More
